The IHC staining and scoring revealed that the expressions of Ki-67 and CD31 were decreased in the treatment group compared with those in the control group, which was consistent with the tumor burdens in the different groups (Supplementary Fig. 7F-H). This evidence concerns the gene PECAM1 and neoplasm.